It was announced on February 27, 2008 that the U.S. Food and Drug Administration (FDA) has accepted Ovation Pharmaceuticals’ new drug applications (NDA) for Sabril® (vigabatrin) in two types of epilepsies. The FDA assigned a priority NDA review for...
On January 14, 2008 Dr. Steven Schachter was guest expert for a question and answer chat on seizure medicines. The purpose of this session was to provide general information and resources. These answers and the information on epilepsy.com are not...
The FDA has issued an alert highlighting concerns that AEDS (called antiepileptic drugs) used for epilepsy may increase the risk of suicidal feelings or behaviors in people taking many of these drugs. This report examined results of some studies...
On July 10, 2008, an advisory panel was convened by the Food and Drug Administration (FDA) to review data that the FDA had previously collected concerning a possible association between many of the antiepileptic drugs (AEDs) that are prescribed to...
The PEP Jobs Program was started by physicians of the Pacific Epilepsy Program (PEP) at California Pacific Medical Center to help people with epilepsy find employment. It helps a wide range of clients, from those who are developmentally disabled to...

Pages